Medical Therapy. Efficacy or Lack of Efficacy

[Risks of magistral preparations in pediatrics]

Charlotte Rosen, Caroline Jacqmart, Corinne Charlier, Maurice Beghetti, Marie-Christine SeghayeCentre Hospitalier Universitaire de Liège. Hôpitaux universitaires de Genève.Belgium and Switzerland Revue Medicale de LiegeRev Med Liege 2024; 79: 104-109DOI: Not Available AbstractVasoreactive pulmonary arterial hypertension (PAH) in children is a form of idiopathic PAH that responds to vasoreactive testing with nitric oxide (NO) by a […]

[Risks of magistral preparations in pediatrics] Read More »

Intra-Amniotic Sildenafil and Rosiglitazone Late in Gestation Ameliorate the Pulmonary Hypertension Phenotype in Congenital Diaphragmatic Hernia

Shino Yoshida, Olivia Eichelberger, Michael Ulis, Alexander M. Kreger, George K. Gittes, Joseph T. ChurchUniversity of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh. University of Michigan Medical School.United States Pediatric SurgeryPediatr Surg 2024;DOI: 10.1016/j.jpedsurg.2024.01.010 AbstractBackground: Pulmonary hypertension remains difficult to manage in congenital diaphragmatic hernia (CDH). Prenatal therapy may ameliorate postnatal pulmonary hypertension. We

Intra-Amniotic Sildenafil and Rosiglitazone Late in Gestation Ameliorate the Pulmonary Hypertension Phenotype in Congenital Diaphragmatic Hernia Read More »

Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension

Justin J. Kochanski, Jeffrey A. Feinstein, Michelle Ogawa, Victor Ritter, Rachel K. Hopper, Gregory T. AdamsonStanford University School of Medicine.United States Pulmonary CirculationPulm Circ 2024; DOI: 10.1002/pul2.12328 AbstractChildren with severe Group 1 pulmonary arterial hypertension (PAH) have an unpredictable response to subcutaneous treprostinil (TRE) therapy, which may be influenced by age, disease severity, or other unknown

Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension Read More »

Successful treatment of pulmonary arterial hypertension in a 2-month-old female infant with incontinentia pigmenti: A case report

Marta Marcia, Paola Coppo, Giuseppe Alberto Annoni, Gaetana Ferraro, Gabriella Agnoletti, Giuseppe Antonio MazzaCity of Health and Science Hospital.Italy Annals of Pediatric CardiologyAnn Pediatr Cardiol 2023; 16: 297-300DOI: 10.4103/apc.apc_75_23 AbstractIncontinentia pigmenti (IP) is a rare X-linked dominant neuroectodermal dysplasia affecting almost exclusively females. It is caused by loss-of-function mutations in the inhibitor of kappa light polypeptide

Successful treatment of pulmonary arterial hypertension in a 2-month-old female infant with incontinentia pigmenti: A case report Read More »

Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension

Michael W. Cookson, John P. KinsellaUniversity of Colorado Anschutz School of Medicine and Children’s Hospital Colorado.United States Clinics in PerinatologyClin Perinatol 2024; 51: 95-111DOI: 10.1016/j.clp.2023.11.001 AbstractPivotal trials investigating the use of inhaled nitric oxide (iNO) in the 1990s led to approval by the Food and Drug Administration in 1999. Inhaled nitric oxide is the only approved

Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension Read More »

Oxygen Targets in Neonatal Pulmonary Hypertension: Individualized, “Precision-Medicine” Approach

Satyan Lakshminrusimha, Steven H. AbmanUniversity of California, Davis Children’s Hospital. University of Colorado Anschutz Medical Campus.United States Clinics in PerinatologyClin Perinatol 2024; 51: 77-94DOI: 10.1016/j.clp.2023.12.003 AbstractOxygen is a specific pulmonary vasodilator. Hypoxemia causes pulmonary vasoconstriction, and normoxia leads to pulmonary vasodilation. However, hyperoxia does not enhance pulmonary vasodilation but causes oxidative stress. There are no clinical

Oxygen Targets in Neonatal Pulmonary Hypertension: Individualized, “Precision-Medicine” Approach Read More »

Randomized Controlled Trials of Pulmonary Vasodilator Therapy Adjunctive to Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn: A Systematic Review

Kristen Coletti, K. Taylor Wild, Elizabeth E. Foglia, Suzan Cochius-den Otter, Haresh KirpalaniChildren’s Hospital of Philadelphia and University of Pennsylvania. Erasmus MC University Medical Center.United States and Netherlands Clinics in PerinatologyClin Perinatol 2024; 51: 253-269DOI: 10.1016/j.clp.2023.11.009 AbstractInhaled nitric oxide (iNO) is a pulmonary vasodilator considered standard of care to treat persistent pulmonary hypertension of the newborn.

Randomized Controlled Trials of Pulmonary Vasodilator Therapy Adjunctive to Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn: A Systematic Review Read More »

Targeted Therapies for Neonatal Pulmonary Hypertension: Beyond Nitric Oxide

Jeanne Carroll, Rohit Rao, Robin H. SteinhornUniversity of California, San Diego and Rady Children’s Hospital. United States Clinics in PerinatologyClin Perinatol 2024; 51: 113-126DOI: 10.1016/j.clp.2023.11.008 AbstractPulmonary hypertension in the neonatal population can be acute or chronic and carries significant risk for morbidity and mortality. It can be idiopathic but more often is associated with comorbid pulmonary

Targeted Therapies for Neonatal Pulmonary Hypertension: Beyond Nitric Oxide Read More »

Recurrent Syncope Unveiling Pulmonary Hypertension Secondary to Pulmonary Artery Thrombi in a Pediatric Patient

Dina AlkhateebAltamimi, Karim Khalidi, Rima Khasawneh, Abdulhadi Alzaben, Khaled SalaymehAl Khalidi Hospital. Yarmouk University. Jordan CureusCureus 2024; 16DOI: 10.7759/cureus.51812 AbstractWe present a case of a nine-year-old female patient who presented with recurrent syncope and was ultimately diagnosed with pulmonary hypertension (PH) secondary to pulmonary artery thrombi in the context of anti-phospholipid syndrome (APS). Extensive investigations including

Recurrent Syncope Unveiling Pulmonary Hypertension Secondary to Pulmonary Artery Thrombi in a Pediatric Patient Read More »

Pulmonary vein stenosis: Anatomic considerations, surgical management, and outcomes

Eric N. Feins, Christina Ireland, Kimberlee Gauvreau, Mariana Chávez, Ryan Callahan, Kathy J. Jenkins, Christopher W. BairdBoston Children’s Hospital and Harvard Medical School.United States Journal of Thoracic and Cardiovascular SurgeryJ Thorac Cardiovasc Surg 2022; 163: 2198-2207DOI: 10.1016/j.jtcvs.2021.10.022 AbstractObjective: The study objective was to evaluate outcomes of pulmonary vein stenosis repair in a large single-center cohort.Methods: Clinical data from

Pulmonary vein stenosis: Anatomic considerations, surgical management, and outcomes Read More »

Scroll to Top